These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Characterization of various classes of protein adducts. Tannenbaum SR; Skipper PL; Wishnok JS; Stillwell WG; Day BW; Taghizadeh K Environ Health Perspect; 1993 Mar; 99():51-5. PubMed ID: 8319659 [TBL] [Abstract][Full Text] [Related]
24. Covalent binding of 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline to albumin and hemoglobin at environmentally relevant doses. Comparison of human subjects and F344 rats. Dingley KH; Freeman SP; Nelson DO; Garner RC; Turteltaub KW Drug Metab Dispos; 1998 Aug; 26(8):825-8. PubMed ID: 9698300 [TBL] [Abstract][Full Text] [Related]
25. Cytochrome P-450 and acetyltransferase expression as biomarkers of carcinogen-DNA adduct levels and human cancer susceptibility. Badawi AF; Stern SJ; Lang NP; Kadlubar FF Prog Clin Biol Res; 1996; 395():109-40. PubMed ID: 8895986 [TBL] [Abstract][Full Text] [Related]
26. Environmental and chemical carcinogenesis. Wogan GN; Hecht SS; Felton JS; Conney AH; Loeb LA Semin Cancer Biol; 2004 Dec; 14(6):473-86. PubMed ID: 15489140 [TBL] [Abstract][Full Text] [Related]
27. 32P-postlabeling assay for carcinogen-DNA adducts and other dna modifications. Randerath K; Randerath E J UOEH; 1989 Mar; 11 Suppl():368-86. PubMed ID: 2664950 [TBL] [Abstract][Full Text] [Related]
28. [Tobacco smoking related DNA and protein adducts and risk of degenerative diseases]. Baer-Dubowska W Przegl Lek; 2006; 63(10):932-5. PubMed ID: 17288187 [TBL] [Abstract][Full Text] [Related]
29. Constitutive and carcinogen-derived DNA binding as a basis for the assessment of potency of chemical carcinogens. Lutz WK Adv Exp Med Biol; 1981; 136 Pt B():1349-65. PubMed ID: 7344514 [TBL] [Abstract][Full Text] [Related]
30. Relevance of urinary DNA adducts as markers of carcinogen exposure. Shuker DE; Farmer PB Chem Res Toxicol; 1992; 5(4):450-60. PubMed ID: 1391611 [No Abstract] [Full Text] [Related]
31. Metabolism and activation of chemical carcinogens. Weisburger EK Mol Cell Biochem; 1980 Sep; 32(2):95-104. PubMed ID: 6161301 [TBL] [Abstract][Full Text] [Related]
32. Mass Spectrometric Characterization of Human Serum Albumin Adducts Formed with N-Oxidized Metabolites of 2-Amino-1-methylphenylimidazo[4,5-b]pyridine in Human Plasma and Hepatocytes. Wang Y; Peng L; Bellamri M; Langouët S; Turesky RJ Chem Res Toxicol; 2015 May; 28(5):1045-59. PubMed ID: 25815793 [TBL] [Abstract][Full Text] [Related]
33. Use of monoclonal and polyclonal antibodies against DNA adducts for the detection of DNA lesions in isolated DNA and in single cells. Baan RA; Zaalberg OB; Fichtinger-Schepman AM; Muysken-Schoen MA; Lansbergen MJ; Lohman PH Environ Health Perspect; 1985 Oct; 62():81-8. PubMed ID: 3910422 [TBL] [Abstract][Full Text] [Related]
34. Aflatoxin-albumin adducts: a basis for comparative carcinogenesis between animals and humans. Wild CP; Hasegawa R; Barraud L; Chutimataewin S; Chapot B; Ito N; Montesano R Cancer Epidemiol Biomarkers Prev; 1996 Mar; 5(3):179-89. PubMed ID: 8833618 [TBL] [Abstract][Full Text] [Related]
35. Molecular epidemiology in cancer risk assessment and prevention: recent progress and avenues for future research. Wogan GN Environ Health Perspect; 1992 Nov; 98():167-78. PubMed ID: 1486846 [TBL] [Abstract][Full Text] [Related]
36. Alkyl and aryl carcinogen adducts detected in human peripheral lung. Wilson VL; Weston A; Manchester DK; Trivers GE; Roberts DW; Kadlubar FF; Wild CP; Montesano R; Willey JC; Mann DL Carcinogenesis; 1989 Nov; 10(11):2149-53. PubMed ID: 2805234 [TBL] [Abstract][Full Text] [Related]
37. Carcinogen hemoglobin adducts, urinary mutagenicity, and metabolic phenotype in active and passive cigarette smokers. Wu JM J Natl Cancer Inst; 1991 Jul; 83(13):963. PubMed ID: 2067040 [No Abstract] [Full Text] [Related]
38. Conservation of histone carcinogen adducts during replication: implications for long-term molecular dosimetry. Ozbal CC; Velic I; SooHoo CK; Skipper PL; Tannenbaum SR Cancer Res; 1994 Nov; 54(21):5599-601. PubMed ID: 7923203 [TBL] [Abstract][Full Text] [Related]
39. The uses of carcinogen-DNA adduct measurement in establishing mechanisms of mutagenesis and in chemoprevention. Baird WM; Mahadevan B Mutat Res; 2004 Mar; 547(1-2):1-4. PubMed ID: 15013693 [TBL] [Abstract][Full Text] [Related]
40. Chemoprevention of carcinogen-DNA adducts and chronic degenerative diseases. Izzotti A; D'Agostini F; Bagnasco M; Scatolini L; Rovida A; Balansky RM; Cesarone CF; De Flora S Cancer Res; 1994 Apr; 54(7 Suppl):1994s-1998s. PubMed ID: 8137327 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]